Cook Medical Provides Patient-Level Paclitaxel Data From Zilver PTX Randomized Controlled Trial


April 18, 2019—Cook Medical announced that patient-level data from the Zilver PTX randomized controlled trial (RCT) of the company's paclitaxel-eluting peripheral stent is available by request on the company's website. The Zilver PTX RCT followed 479 patients for 5 years in the United States, Germany, and Japan. For more information about Zilver PTX, and to request access to the patient-level data, visit

Cook stated that it provides this data to encourage further collaboration with researchers to benefit patients with peripheral artery disease.

To ensure the privacy and confidentiality of the patients involved, Cook has reviewed the data provided and deidentified it as necessary to mitigate identification risk. The data is intended for noncommercial research purposes only and will be provided at no charge.

In the announcement, Mark Breedlove, vice president of Cook Medical’s Vascular Division, stated, “We will continue to support our customers and their patients by sharing what we’ve discovered from our research and data in the area of paclitaxel.”

For all news related to the ongoing controversy regarding paclitaxel use in PAD, please visit Endovascular Today's comprehensive continuing coverage page.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.